| __timestamp | Agios Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 91733000 |
| Thursday, January 1, 2015 | 35992000 | 87644000 |
| Friday, January 1, 2016 | 50714000 | 92365000 |
| Sunday, January 1, 2017 | 71124000 | 85656000 |
| Monday, January 1, 2018 | 114145000 | 88196000 |
| Tuesday, January 1, 2019 | 132034000 | 89971000 |
| Wednesday, January 1, 2020 | 149070000 | 93413000 |
| Friday, January 1, 2021 | 121445000 | 91355000 |
| Saturday, January 1, 2022 | 121673000 | 113676000 |
| Sunday, January 1, 2023 | 119903000 | 198366000 |
| Monday, January 1, 2024 | 156784000 | 218935000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, understanding the financial dynamics of companies is crucial. Over the past decade, Agios Pharmaceuticals and Taro Pharmaceutical Industries have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Agios Pharmaceuticals saw a significant increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014. However, a slight decline was observed in 2023. In contrast, Taro Pharmaceutical Industries maintained a relatively stable SG&A expenditure until 2022, when it surged by 75% in 2023. This divergence highlights Agios's aggressive growth strategy, while Taro's recent spike suggests a strategic shift. Missing data for Agios in 2024 indicates potential reporting changes or strategic pivots. These insights provide a window into the operational strategies of these pharmaceutical giants, offering investors and analysts a deeper understanding of their financial health.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.